Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100623Source: DataRank Database

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets is a research paper published in JTO Clinical and Research Reports (2023). On theSindex it has a DataRank of 0.504. It has been cited 12 times, with 11 citing works in its 1-hop citation network.

N/A

0.504DataRank · unranked

Scored on demand from live citation data

Open Access12 citations · 11 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)OA: goldTopics (20)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 76%Citation Network 24%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

0.119

From 9 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 11 citers.

Prevalence, treatment patterns, and survival of patients with brain metastases from small cell lung cancer: A retrospective study using the TriNetX Oncology Database
Neuro-Oncology Practice20243 citations51 referencesContributes 0.027
The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies
Critical Reviews in Oncology/Hematology20256 citations105 referencesContributes 0.019
Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications
Cancers20258 citations120 referencesContributes 0.018
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Cancer202514 citations154 referencesContributes 0.018
Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors
Annals of Diagnostic Pathology20252 citations76 referencesContributes 0.014

Authors (36)

Whitney E. Lewis ORCID,C. Allison Stewart ORCID,Benjamin B. Morris ORCID,Luisa M. Solis,Alejandra G. Serrano ORCID

Live enrichment

PubMed:38357092 PMC:PMC10864847

National Cancer Institute

Grant: P30-CA016672

National Cancer Institute

Grant: P50-CA070907

National Cancer Institute

Grant: R01-CA207295

National Cancer Institute

Grant: R50-CA243698

National Cancer Institute

Grant: U01-CA256780

Cancer Prevention and Research Institute of Texas

Grant: RP210028

Cancer Prevention and Research Institute of Texas

Grant: T32-CA009666

NCI NIH HHS

Grant: R50 CA243698

NCI NIH HHS

Grant: P50 CA070907

NCI NIH HHS

Grant: R01 CA207295

National Institutes of Health

Grant: 5U01CA256780-04

Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response

National Institutes of Health

Grant: 5R50CA243698-02

Modeling tumor heterogeneity and treatment resistance in small cell lung cancer

National Institutes of Health

Grant: 3P50CA070907-02S1

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCER

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5T32CA009666-08

TRAINING FOR ACADEMIC ONCOLOGY

National Institutes of Health

Grant: 5R01CA207295-09

DNA damaging therapy and immune response in small cell lung cancer subtypes

National Institutes of Health

Damon Runyon Cancer Research Foundation

V Foundation for Cancer Research

Computer Modelling Group

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.jtocrr.2023.100623

publisherhttps://api.elsevier.com/content/article/PII:S2666364323001662?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364323001662?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10864847/pdf/main.pdf

Europe_PMChttps://europepmc.org/articles/PMC10864847

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

Keywords

Resistance mechanismNSCLCSCLCCell Surface TargetHistologic TransformationOsimertinibMedical SciencesBioinformaticsBrief Report610Neoplasms. Tumors. Oncology. Including cancer and carcinogens600Biomedical InformaticsOncologyMedical SpecialtiesMedicine and Health SciencesRC254-282

Sustainable Development Goals

SDG 3: 3. Good health